1. Antibody engineering: We are engineering and investigating bispecific antibodies to deliver nanomedicines into cancer cells for improved anticancer selectivity and efficacy. 2. Nanomedicine: New approaches to stably load and retain hydrophobic drugs in liposomal nanocarriers are under development. 3. Directed molecular evolution: We have developed powerful screening methodology to perform directed molecular evolution of human enzymes. We are employing this technology to improve the properties of proteins to treat genetic diseases and for antibody-directed enzyme prodrug therapy. Methods to rapidly evolve high affinity antibodies directly in hybridoma cells are also under investigation. 4. Prodrug therapy: Anticancer prodrugs that are selectively activated in the tumor microenvironment are under investigation to improve the selectivity and therapeutic efficacy of cancer treatment. The mechanisms of selective prodrug activation and strategies to improve selectivity are under investigation. 5. Anti-PEG antibodies: We have developed antibodies to assay PEGylated drugs in human serum and are extending these studies to investigating the impact of pre-existing and induced anti-PEG antibodies on the therapeutic efficacy of PEGylated medicines.
1. 抗體工程：建構雙特異性抗體抗體，用以遞送奈米藥物至腫瘤，改善癌症治療的選擇性與療效。2. 奈米醫藥：正在研發新穎的技術，將疏水性藥物穩定包覆於奈米微脂體。3. 定向分子演化：本實驗室已研發出有力的篩選方法，分選出定向演化後的優化人類酵素。我們以此技術提高蛋白質的性能，應用於治療遺傳疾病，與抗體-酵素前驅藥物療法。此外，本實驗室亦發展於抗體融合瘤細胞中，快速演化高親和力抗體的技術。4. 前驅藥物療法：發展在腫瘤微環境內能夠優先被活化的前驅藥物，瞭解其機制以及改善活化的條件。5. 聚乙二醇抗體：本實驗室研發聚乙二醇抗體，用以檢測人類血液檢體中聚乙二醇修飾藥物含量。我們亦延伸相關研究，探討人體中已存在，或被誘發產生的聚乙二醇抗體，是否會影響聚乙二醇修飾醫藥的療效。